newsfilter
← Latest News
Business Wire·

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) (the "Company" or "Merrimack"), announced today that its Board of Directors (the "Board") has extended the Section 382 net operating loss rights plan (the "Plan") that was